mRNA-CR-04 / GSK - LARVOL DELTA

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults (clinicaltrials.gov) - P1 | N=114 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | N=72 ➔ 114

Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases